Is Curanex Pharmaceuticals going out of business?

Curanex Pharmaceuticals Inc (CURX) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

Curanex Pharmaceuticals Inc (CURX) scores 17 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Shares dilution YoY: Reverse split detected; adjusted share change (18.1% YoY) and the capital-structure risk is penalized.

Five questions, kept separate

Survival - Critical

2-4 mo of estimated runway from 2026-06-30, based on $2.9M of cash and short-term investments against $13.5M of annual burn. A disclosed filing event caps this reading; Event Risk carries the detail.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Undemanding

65.2% net-cash backing support an undemanding pre-commercial Valuation assessment.

Event risk - Critical event risk

Going-Concern Warning is the decisive filing event; one adverse event family is active. It appears across 2 scanned filings. Favorable events are shown separately and do not offset adverse risk.

What the rules read

• Shares dilution YoY: Reverse split detected; adjusted share change (18.1% YoY) and the capital-structure risk is penalized.
• Debt / Equity: -0.56x (Net Cash)
• ROIC: -102.80%
• Filing event risk: Going-Concern Warning (-8 pts)
• Return on Assets: -83.27%
• Price / Earnings: Unprofitable (see Valuation)

Read from filings through 2026-09-04.

Price as of 2026-09-07.